<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>328(6)</volume><submitter>Sandner S</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>The role of ticagrelor with or without aspirin after coronary artery bypass graft surgery remains unclear.&lt;h4>Objective&lt;/h4>To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery.&lt;h4>Data sources&lt;/h4>MEDLINE, Embase, and Cochrane Library databases from inception to June 1, 2022, without language restriction.&lt;h4>Study selection&lt;/h4&gt;Randomized clinical trials (RCTs) comparing the effects of ticagrelor DAPT or ticagrelor monotherapy vs aspirin on saphenous vein graft failure.&lt;h4>Data extraction and synthesis&lt;/h4>Individual patient data provided by each trial were synthesized into a combined data set for independent </pubmed_abstract><journal>JAMA</journal><pagination>554-562</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9364127</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.</pubmed_title><pmcid>PMC9364127</pmcid><pubmed_authors>Audisio K</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Fremes SE</pubmed_authors><pubmed_authors>Starovoytov A</pubmed_authors><pubmed_authors>Gaudino M</pubmed_authors><pubmed_authors>Redfors B</pubmed_authors><pubmed_authors>Saw J</pubmed_authors><pubmed_authors>Angiolillo DJ</pubmed_authors><pubmed_authors>Ten Berg JM</pubmed_authors><pubmed_authors>Zhao Q</pubmed_authors><pubmed_authors>Peper J</pubmed_authors><pubmed_authors>Janssen PWA</pubmed_authors><pubmed_authors>Kulik A</pubmed_authors><pubmed_authors>Ruel M</pubmed_authors><pubmed_authors>Soletti GJ</pubmed_authors><pubmed_authors>Sandner S</pubmed_authors><pubmed_authors>Willemsen LM</pubmed_authors><pubmed_authors>Mehran R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.</name><description>&lt;h4>Importance&lt;/h4>The role of ticagrelor with or without aspirin after coronary artery bypass graft surgery remains unclear.&lt;h4>Objective&lt;/h4>To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery.&lt;h4>Data sources&lt;/h4>MEDLINE, Embase, and Cochrane Library databases from inception to June 1, 2022, without language restriction.&lt;h4>Study selection&lt;/h4&gt;Randomized clinical trials (RCTs) comparing the effects of ticagrelor DAPT or ticagrelor monotherapy vs aspirin on saphenous vein graft failure.&lt;h4>Data extraction and synthesis&lt;/h4>Individual patient data provided by each trial were synthesized into a combined data set for independent </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-18T23:28:46.688Z</modification><creation>2025-04-07T11:03:23.393Z</creation></dates><accession>S-EPMC9364127</accession><cross_references><pubmed>35943473</pubmed><doi>10.1001/jama.2022.11966</doi></cross_references></HashMap>